報價延遲最少15分鐘:2024/12/24 12:36 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.6651 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.37/-0.24
|
|
企業價值
252.90M
|
| 資產負債 |
|
每股賬面淨值
2.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
30.84M
|
|
每股收益
0.50
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:36 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase. |